Sonoma Pharmaceuticals, Inc. (SNOA) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2026, Sonoma Pharmaceuticals reported revenue of $19.5M, up 36.7% from $14.3M the year before. Net income was -$3.2M (a -16.3% net margin), or -$1.89 per diluted share. Gross margin was 38.0% and operating margin was -12.6%. Operating activities generated -$3.9M of cash, leaving -$4.1M of free cash flow. At fiscal year end, Sonoma Pharmaceuticals held $14.0M in total assets against $10.9M in total liabilities, including $2.4M of cash and equivalents.
Open the full interactive Sonoma Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Sonoma Pharmaceuticals Key Stats
| Share Price | $1.18 |
|---|---|
| Market Cap | $4.5M |
| Revenue YoY Growth | +36.7% |
| 52-Week Range | $1.01 – $4.08 |
| Shares Outstanding | 3.8 million (basic, 2027 Q1) |
Sonoma Pharmaceuticals Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $18.6M | $12.6M | $13.3M | $12.7M | $14.3M | $19.5M |
| Cost of Goods Sold | $12.1M | $8.6M | $8.8M | $8.0M | $8.8M | — |
| Gross Profit | $6.6M | $4.0M | $4.5M | $4.7M | $5.5M | $7.4M |
| Operating Income | -$3.4M | -$5.9M | -$4.6M | -$4.7M | -$3.7M | -$2.5M |
| Pre-Tax Income | -$3.9M | -$5.4M | -$5.2M | -$5.0M | -$2.9M | -$3.4M |
| Income Tax | $713,000 | -$332,000 | -$33,000 | -$196,000 | $550,000 | -$244,000 |
| Net Income | -$4.0M | -$5.1M | -$5.2M | -$4.8M | -$3.5M | -$3.2M |
| Diluted EPS | -$39.40 | — | -$30.40 | -$10.60 | -$2.79 | -$1.89 |
Sonoma Pharmaceuticals Quarterly Results
| 2026 Q2 | 2026 Q3 | 2026 Q4 | 2027 Q1 | |
|---|---|---|---|---|
| Revenue | $5.6M | $4.3M | $5.6M | $6.4M |
| Net Income | -$534,000 | -$819,000 | -$581,000 | -$330,000 |
| Diluted EPS | -$0.32 | -$0.48 | -$0.35 | -$0.09 |
Sonoma Pharmaceuticals Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.2M | $7.4M | $3.8M | $3.1M | $5.4M | $2.4M |
| Current Assets | $13.0M | $16.4M | $13.8M | $12.5M | $12.6M | $12.1M |
| Total Assets | $15.0M | $18.8M | $16.2M | $14.7M | $13.7M | $14.0M |
| Current Liabilities | $4.1M | $5.8M | $3.7M | $3.7M | $4.1M | $4.8M |
| Total Long-Term Debt | $1.9M | $120,000 | — | — | — | — |
| Total Liabilities | $9.6M | $10.1M | $8.3M | $8.6M | $9.3M | $10.9M |
| Shareholders' Equity | $5.4M | $8.7M | $8.0M | $6.1M | $4.4M | $3.1M |
Sonoma Pharmaceuticals Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$3.4M | -$4.2M | -$6.2M | -$2.4M | -$88,000 | -$3.9M |
| Cash From Investing | $388,000 | -$99,000 | -$258,000 | -$2,000 | -$80,000 | -$192,000 |
| Cash From Financing | $3.3M | $7.4M | $2.5M | $1.7M | $3.0M | $477,000 |
| Free Cash Flow | -$3.6M | -$4.4M | -$6.4M | -$2.4M | -$168,000 | -$4.1M |
Figures from Sonoma Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Sonoma Pharmaceuticals financials page for every line item.
Sonoma Pharmaceuticals Company Profile
| Ticker | SNOA |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Boulder, Colorado |
| Incorporated in | Delaware |
| Fiscal Year End | March 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001367083 |
Frequently Asked Questions
What was Sonoma Pharmaceuticals' revenue in fiscal 2026?
Sonoma Pharmaceuticals (SNOA) reported revenue of $19.5M for fiscal 2026.
What is Sonoma Pharmaceuticals' annual revenue history?
Sonoma Pharmaceuticals' annual revenue by fiscal year: 2021: $18.6M; 2022: $12.6M; 2023: $13.3M; 2024: $12.7M; 2025: $14.3M; 2026: $19.5M.
What was Sonoma Pharmaceuticals' net income in fiscal 2026?
Sonoma Pharmaceuticals reported net income of -$3.2M for fiscal 2026.
What was Sonoma Pharmaceuticals' earnings per share (EPS) in fiscal 2026?
Sonoma Pharmaceuticals' diluted EPS was -$1.89 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Sonoma Pharmaceuticals generate in fiscal 2026?
Sonoma Pharmaceuticals generated -$4.1M of free cash flow in fiscal 2026.
What was Sonoma Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2027 Q1), Sonoma Pharmaceuticals reported revenue of $6.4M.
How many shares of Sonoma Pharmaceuticals are outstanding?
Sonoma Pharmaceuticals reported a weighted average of 3.8 million basic shares outstanding in 2027 Q1.
What is Sonoma Pharmaceuticals' market cap?
Based on its latest closing price, Sonoma Pharmaceuticals (SNOA) has a market capitalization of about $4.5M.
When does Sonoma Pharmaceuticals' fiscal year end?
Sonoma Pharmaceuticals' fiscal year end, as registered with the SEC, is March 31.
Where is Sonoma Pharmaceuticals headquartered?
Sonoma Pharmaceuticals lists its business address in Boulder, Colorado in its SEC filings.
Sonoma Pharmaceuticals Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →